A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes

Samantha V. Wilkinson1, Laurie A. Tomlinson1, Masao Iwagami1, Heide A. Stirnadel-Farrant2, Liam Smeeth1, Ian Douglas1

1Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
2RWD & Epidemiology, GSK R&D, Stevenage, SG1 2NY, UK

Abstract

Background: The development of kidney disease is a serious complication among people with type 2 diabetes mellitus, associated with substantially increased morbidity and mortality. We aimed to summarise the current evidence for the relationship between treatments for type 2 diabetes and long-term kidney outcomes, by conducting a systematic search and review of relevant studies.

Methods: We searched Medline, Embase and Web of Science, between 1st January 1980 and 15th May 2018 for published clinical trials and observational studies comparing two or more classes of oral therapy for type 2 diabetes. We included people receiving oral antidiabetic drugs. Studies were eligible that; (i) compared two or more classes of oral therapy for type 2 diabetes; (ii) reported kidney outcomes as primary or secondary outcomes; (iii) included more than 100 participants; and (iv) followed up participants for 48 weeks or more. Kidney-related outcome measures included were incidence of chronic kidney disease, reduced eGFR, increased creatinine, ‘micro’ and ‘macro’ albuminuria.

Results: We identified 15 eligible studies, seven of which were randomised controlled trials and eight were observational studies. Reporting of specific renal outcomes varied widely. Due to variability of comparisons and outcomes meta-analysis was not possible. The majority of comparisons between treatment with metformin or sulfonylurea indicated that metformin was associated with better renal outcomes. Little evidence was available for recently introduced treatments or commonly prescribed combination therapies.

Conclusions: Comparative evidence for the effect of treatments for type 2 diabetes on renal outcomes, either as monotherapy or in combination is sparse.

Keywords

Review, Kidney Diseases, Comparative Effectiveness Research, Diabetes Mellitus, Type 2, Hypoglycemic Agents
Corresponding author: Samantha V. Wilkinson (Samantha.Wilkinson@lshtm.ac.uk)

Author roles: Wilkinson SV: Conceptualization, Data Curation, Formal Analysis, Investigation, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Tomlinson LA: Conceptualization, Formal Analysis, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Iwagami M: Investigation, Validation, Writing – Review & Editing; Stirnadel-Farrant HA: Conceptualization, Supervision, Writing – Review & Editing; Smeeth L: Conceptualization, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; Douglas I: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: SW is funded by a GSK PhD scholarship. HS is an employee of and holds shares in GSK. LAT reports no competing interests. IJD is funded by, holds stock in and has consulted for GSK and AstraZeneca, has received grants from the European Union and is a Trustee of the British Heart Foundation.

How to cite this article: Wilkinson SV, Tomlinson LA, Iwagami M et al. A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes [version 1; referees: 1 approved] Wellcome Open Research 2018, 3:74 (doi: 10.12688/wellcomeopenres.14660.1)

Copyright: © 2018 Wilkinson SV et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: This work was was supported by the Wellcome Trust through a Wellcome Trust intermediate clinical fellowship to LAT [101143] and a Wellcome Trust Senior Research Fellowship in Clinical Science to LS [098504] This review was also supported by GlaxoSmithKline (GSK), through a PhD scholarship for SW. HS-F is a full-time employee of GSK. MI is supported by the Honjo International Scholarship Foundation. IJD is paid by an unrestricted grant from GSK.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Introduction
Type 2 diabetes mellitus (DM) increases an individual’s risk for health problems including cardiovascular disease, blindness, chronic kidney disease (CKD), and nerve damage1-4. The development of kidney disease is associated with other complications of type 2 diabetes and with poorer outcomes1,3,5. Therefore, slowing the development of, or preventing kidney disease is one aim of therapy5. Type 2 diabetes drugs are thought to play a major role in protecting the kidneys by controlling blood sugar levels and may confer additional protective effects according to specific drug profiles5. However, as kidney function declines, type 2 diabetes drug options become limited due to prescribing restrictions1,3,5,7. This presents a challenge for treating type 2 diabetes in patients with non-diabetic related kidney disease, as well as those with renal diabetic complications.

Treatment choice reflects a complex balancing of expected risks and benefits. A recent systematic review focused on vascular outcomes, glycaemia, HbA1c, body weight, hypoglycaemia and common adverse events6. Here we focus on kidney-related outcomes as another important aspect of clinical care that clinicians must consider when prescribing drugs for type 2 DM. Our aim was to provide a summary of the current evidence of long term kidney outcomes, from comparative, long terms studies of oral antidiabetic drugs. We included the following outcomes: change in kidney function (estimated glomerular filtration rate), progression or development of proteinuria, development of end-stage renal disease (ESRD) and composite outcomes compared between different oral drugs for the treatment of type 2 DM.

Methods
The protocol for this systematic review was submitted, reviewed and approved by PROSPERO (International prospective register of systematic reviews, ref. 2016: CRD42016036646). The study was conducted and is reported in accordance with the PRISMA protocol (Supplementary File 1)8.

Data sources and searches
We searched the databases: Medline, Embase and Web of Science for articles published between 1st January 1980 and 15th May 2018. The search comprised keywords and MESH terms relating to three broad themes: kidney function, type 2 diabetes drugs and clinical studies. We limited the search to English-language studies, and studies in humans. The search strategies are in Supplementary Table 1 and Supplementary Table 2 (Supplementary File 2). The reference lists of relevant reviews identified through the search were also screened.

Study selection
One reviewer (SW) screened all citations identified in the searches. Titles and abstracts for all studies were compared to the selection criteria. Then the full-text of selected studies were reviewed against the inclusion and exclusion criteria. Reviewer two (MI) was blinded to the articles selected by reviewer one and screened a 20% sample of the articles selected by reviewer one after the title screen. The studies chosen by the two reviewers were compared.

We defined the search and screening strategies before completing the searches. Studies were eligible for inclusion if they were clinical studies that (i) compared two or more classes of oral therapy for type 2 DM; (ii) reported kidney outcomes as primary or secondary outcomes; (iii) included more than 100 participants, and (iv) followed participants for 48 weeks or more. We restricted the review to oral antidiabetic drugs recommended at the initiation and first intensification of treatment6.

We did not include studies that reported only placebo-controlled comparisons as we were interested in the difference in effects between active therapy regimes to reflect therapy choices made in routine clinical care; placebo-controlled studies would not estimate this difference. Our definition of a kidney outcome was broad to identify as many studies as possible. We accepted any kidney-related outcome, including the incidence of chronic kidney disease, reduced estimated Glomerular Filtration Rate (eGFR), increased creatinine, ‘micro’ and ‘macro’ albuminuria, proteinuria, end stage renal disease (ESRD) and composite kidney outcomes. We did not include composite microvascular outcomes that combined kidney outcomes with other microvascular outcomes such as retinopathy or neuropathy.

Data extraction and quality assessment
After study selection, using a predefined data collection tool, we extracted data for the following items: number of participants, study design, calendar years covered by the study, length of follow-up, drug comparison, mean age of study population, exclusion criteria for study, kidney measurements taken at baseline, mean duration of diabetes, mean HbA1c at baseline, primary outcome for the study, kidney outcomes reported and results for kidney outcomes reported. Reviewer one (SW) assessed each study for quality, using the GRACE 201410 items for observational comparative effectiveness research and the Cochrane Collaboration tool for assessing risk of bias in randomised trials11 for RCTs.

Results
Figure 1 details the study selection process through which we found 9,086 potentially eligible studies. The first reviewer (SW) completed the initial title screen and selected 1,896 articles. The second reviewer (MI) was blinded and reviewed a 20% random sample of these articles. The agreement between reviewers was good, reviewer two selected an additional paper that was rejected after discussion. After subsequent discussions (SW, MI and LT), we selected 15 studies.

We identified 15 eligible studies, seven of which were randomised controlled trials (RCTs)2-18 and eight were observational studies19-24. Across the 15 studies, three RCTs16-18 and one observational study22, reported changes in eGFR as an outcome. All seven RCTs15-18 and two observational studies22,23 investigated albumin-creatinine ratio (ACR) as an outcome. Six observational studies reported kidney endpoints, including kidney failure, nephropathy, acute dialysis and composite endpoints with eGFR19-21,23,24,26. Comparisons made, and outcomes studied are summarised graphically in Figure 2. Given the range of the kidney function outcomes reported and the drug class comparisons
made we did not complete a meta-analysis of the results, instead we provide a narrative summary of studies. Selected studies and their findings are summarised in Table 1 and Table 2.

In total, we identified 32 direct comparisons between oral drugs for the treatment of type 2 DM: 22 comparisons between monotherapies, three comparisons between dual therapy combinations, and seven comparisons between dual therapies and monotherapies, outlined in Table 3. One study compared many combination therapy options to metformin; we did not include the triple therapy combinations from this study in our results, details of the comparisons are in Supplementary Table 3 (Supplementary File 2).

Monotherapy comparisons

Metformin monotherapy vs. thiazolidinedione monotherapy. The most common drug comparison was metformin monotherapy vs. thiazolidinedione monotherapy (five studies made seven comparisons)\(^1\,\!^4\,\!^6\,\!^9\,\!^2\,\!^2\,\!^3\,\!^2\,\!^2\). Two RCTs found that thiazolidinediones were associated with improved kidney outcomes (reduced proteinuria or improved eGFR) compared to metformin\(^1\,\!^4\,\!^6\). While two observational studies found no differences between the two drug classes\(^9\,\!^2\,\!^3\). One observational cohort study showed that thiazolidinediones were associated with a higher risk for development of kidney failure (a composite of kidney dialysis, kidney transplant and CKD stage five) compared to metformin\(^2\,\!^3\).

Metformin monotherapy vs. sulfonylurea monotherapy. Six observational studies\(^\!^9\,\!^1\,\!^6\,\!^2\,\!^6\,\!^2\,\!^6\,\!^2\,\!^2\,\!^2\) compared metformin monotherapy to sulfonylurea monotherapy. Though two of these studies (19 and 20) reported similar findings from the same source population, we have therefore only reported one of the results, making six comparisons. Four comparisons favoured metformin. One study found the risk of eGFR falling to below 60 mL/min/1.73m\(^2\) was greater in the sulfonylurea group compared to the metformin group\(^2\,\!^2\). Three found higher risks of kidney failure outcomes (various composites of codes for nephropathy, dialysis, renal transplant, ESRD, and reductions in eGFR) for sulfonylurea compared to metformin\(^9\,\!^2\,\!^6\,\!^2\,\!^2\). One study, using proteinuria as an outcome, found no difference between drug classes\(^9\). One further study reported higher rates of acute dialysis for people initiating metformin compared to sulfonylureas\(^2\).

Sulfonylurea monotherapy vs. thiazolidinedione monotherapy. Findings from two RCTs showed differences in ACR that were not statistically significant\(^1\,\!^4\,\!^6\). However, one of these studies also showed an increase in mean eGFR among patients treated with a TZD, but a fall in the SU group\(^1\,\!^4\).

Figure 1. Flow diagram of study selection. Ovid was used to search the Embase and Medline databases.
Sulfonylurea monotherapy vs. SGLT2i monotherapy. One RCT showed canagliflozin slowed kidney function decline, and reduced albuminuria, compared to glimepiride. Combination therapy comparisons

Only three studies compared combination therapies.

Metformin plus sulfonylurea vs. metformin plus thiazolidinedione. One RCT compared metformin plus sulfonylurea to metformin plus a thiazolidinedione. They reported that ACR decreased in the metformin plus thiazolidinedione group and increased in the metformin plus sulfonylurea group.

Sulfonylurea plus metformin vs. sulfonylurea plus thiazolidinedione. One RCT compared sulfonylurea plus metformin to sulfonylurea plus thiazolidinedione. The study found that the ACR increased in the sulfonylurea plus metformin group, and decreased in the sulfonylurea plus thiazolidinedione group.

Metformin plus sulfonylurea vs. metformin plus gliptin (DPP4i). One observational study compared metformin plus sulfonylurea combination therapy to metformin plus sitagliptin. The results showed weak evidence that metformin plus sitagliptin improved the likelihood of reductions in ACR, with an odds ratio of 1.20 (95% CI: 0.99–1.47, P = 0.063).

Dual therapy vs. monotherapy

Three observational studies made seven comparisons between monotherapy options and combination therapy. One study indicated that people taking metformin were at a lower risk of renal failure compared to people taking metformin plus sulfonylurea. Another study found the opposite, people taking metformin plus sulfonylurea were at lower risk of kidney failure compared to metformin. The same study found no differences in the risk of kidney failure compared to metformin in people prescribed i) metformin plus thiazolidinedione, and ii) metformin plus gliptin. They also reported that people prescribed sulfonylurea plus thiazolidinedione, and a sulfonylurea plus DPP4i were at higher risk for kidney failure compared to metformin.

Another observational study found no difference in eGFR outcomes between sulfonylurea monotherapy and metformin plus sulfonylurea combination therapy.

Study quality

We assessed each study for quality, using the GRACE 2014 items for observational comparative effectiveness research and the Cochrane Collaboration risk of bias tool for RCTs. Supplementary Table 5 and Supplementary Table 6 detail the results. For the RCTs, we assessed study quality as good, though few studies reported details of randomisation techniques. Of the observational studies, reporting was reasonable, according to the GRACE criteria. However, many of the studies made comparisons between drugs used at different stages of drug intensification, or between monotherapy and combination therapy. For example, two observational studies used metformin monotherapy as the baseline in comparisons with combination therapy. As metformin monotherapy is the
<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Number</th>
<th>Follow-up</th>
<th>Drug comparison</th>
<th>Mean age (yrs)</th>
<th>Exclusions†</th>
<th>Inclusions†</th>
<th>Measures at baseline</th>
<th>Primary outcomes of study</th>
<th>Kidney outcomes recorded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakris et al (2003)</td>
<td>121^a</td>
<td>52w</td>
<td>SU, TZD (GLY, RSG)</td>
<td>55.6</td>
<td>Prior use of ACEI, ARBs, BB or CCBs</td>
<td>40-80 yrs with type 2 DM</td>
<td>28% microalbuminuria b Baseline ACR NR</td>
<td>GLY: 9.5 (1.6) RSG: 9.1 (17)</td>
<td>52 w Microalbuminuria resolved in: RSG: 43%, GLY: 6% ACR mean % change: RSG: -23, GLY: -8</td>
</tr>
<tr>
<td>Hanefeld et al (2004)</td>
<td>639</td>
<td>52w</td>
<td>SU+TZD, SU+MTF (SU+PGZ, SU+MTF)</td>
<td>60</td>
<td>Previous cardiac events, malignant disease in 6 months before study. Previous treatment with MTF or TZD</td>
<td>35-75yrs with type 2 diabetes inadequately managed with SU monotherapy with HbA1c 7.5-11.0%</td>
<td>28% albuminuria c Mean ACR (SD) SU+PGZ: 0.07 (0.25) SU+MTF: 0.11 (0.56)</td>
<td>SU+PGZ: 8.8 (0.98) SU+MTF: 8.8 (0.97) HbA1c at week 52, FPG, Insulin and lipid profiles.</td>
<td>52 w Microalbuminuria resolved in: SU+PGZ: 10.2%, SU+MTF: 7.7% ACR mean % change: SU+PGZ: -15, SU+MTF: +2</td>
</tr>
<tr>
<td>Schernthaner et al (2004)</td>
<td>1199</td>
<td>12m</td>
<td>MTF, TZD (MTF, PGZ )</td>
<td>56.5</td>
<td>Use of thiazides but other antihypertensives allowed</td>
<td>People inadequately treated with diet alone, or HbA1c 7.5-11%</td>
<td>Mean ACR (SD) MTF+PGZ: 0.06 (0.14) MTF+GLZ: 0.05 (0.16)</td>
<td>SU+Pio: 8.7 (0.1) MTF: 8.7 (1) HbA1c</td>
<td>52 w ACR mean % change: PGZ: -19, MTF: -1</td>
</tr>
<tr>
<td>Matthews et al (2005)</td>
<td>630</td>
<td>52w</td>
<td>MTF+TZD, MTF+SU (MTF+PGZ, MTF+GLZ )</td>
<td>56.5</td>
<td>Ketoacidosis, MI, TIA, stroke in the previous 6m; symptomatic heart failure; acute malabsorption or chronic pancreatitis; familial polyposis coli; malignant disease in past 10ys; substance abuse</td>
<td>Previously not managed with MTF monotherapy. Hba1c 7.5-11%. No previous treatment with insulin, gliclazide, pioglitazone, SU/ T2ZD</td>
<td>Mean ACR (SD) MTF+PGZ: 0.06 (0.14) MTF+GLZ: 0.05 (0.16)</td>
<td>SU+Pio: 8.7 (0.1) SU+MTF: 8.53 (0.9) HbA1c</td>
<td>52 w ACR mean % change: MTF+PGZ: -10, MTF+GLZ: +6</td>
</tr>
<tr>
<td>ADOPT Lachin et al (2011)</td>
<td>4351</td>
<td>5yrs</td>
<td>TZD, MTF, SU (RSG, MTF, GLY)</td>
<td>56.9</td>
<td>Significant liver disease, kidney impairment (serum creatinine males: &gt;1.3mg, females: &gt;1.2mg), history of lactic acidosis, anemia, congestive heart failure uncontrolled hypertension</td>
<td>≥3yrs history of type 2 DM, FPG 7-10mmol/L</td>
<td>16% albuminuria: Mean ACR (log transformed) RSG 9.9 (180), MTF 9.3 (172), GLY 9.4 (172) Mean eGFR (geometric) RSG 98.0 (24.6), MTF 97.1 (25.6), GLY 95.7 (27.6)</td>
<td>RSG: 7.36 (0.93) MTF: 7.36 (0.93) GLY: 7.35 (0.92) Time to drug failure, using FPG</td>
<td>4 yr Albuminuril resolved in: RSG: 69.5%, MTF: 64%, GLY: 64% ACR mean change (95% CI): RSG 21.7(-4.2, 8.8), MTF 20.9 (13.3, 28.9), GLY 6.1 (-1.2, 14.0) eGFR mean change % (95% CI): RSG: 5.1 (3.6-6.7), MTF: 1.4 (0.0, 2.9), GLY: -0.4 (-2.1, 1.2)</td>
</tr>
<tr>
<td>Author (Year)</td>
<td>Number</td>
<td>Follow-up</td>
<td>Drug comparison</td>
<td>Mean age (yrs)</td>
<td>Exclusions</td>
<td>Inclusions</td>
<td>Kidney measures</td>
<td>Proteinuria/ Mean ACR/ eGFR</td>
<td>Yrs with T2DM</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>-----------</td>
<td>----------------</td>
<td>---------------</td>
<td>------------</td>
<td>------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Pan et al (2016)</td>
<td>762</td>
<td>48w</td>
<td>ACA, MTF</td>
<td>50</td>
<td>History of cardiac disease, kidney disease, uncontrolled hypertension, urinary infection</td>
<td>Newly diagnosed type 2 diabetes within 1 yr: &gt;1 month of treatment with type 2 diabetes in previous 12m and no treatment 3 months prior.</td>
<td>Elevated ACR: ACA 20%, MTF 24%</td>
<td>Mean Median ACR (IQR): ACA: 12.5 (4.9-25.8), MTF 11.6 (5.3-28.8)</td>
<td>Mean eGFR (SD): ACA: 109.6 (29.8), MTF 114.9 (32.3)</td>
</tr>
<tr>
<td>CANTATA-SU Heerspink et al (2017)</td>
<td>1450</td>
<td>104w</td>
<td>SGLT, SU (CNG, GLM)</td>
<td>56.2</td>
<td>eGFR &gt;60, last 6 months severe hypoglycaemia, serum creatinine (μmol/L) (men &gt;124, women &gt;115), T2D in last 16 weeks</td>
<td>18-80 yrs with type 2 DM, HbA1c 7-9.5 %. managed with MTF therapy</td>
<td>Mean ACR: GLM: 7.8 (0.8)</td>
<td>CNG 100mg: -5.7 (2.2, -13.1), CNG 300mg: -11.2 (-3.6, -18.3)</td>
<td>Mean change (95 CI): GLM: -5.4 (-6.2, -4.5), CNG 100mg: -2.7 (-3.5, -1.9), CNG 300mg: -3.9 (-4.7, -3.0) Incidence of 30% eGFR decline HR (95% CI): Referent GLM CNG 100mg: 0.66 (0.42, 1.04), CNG 300mg: 0.93 (0.62, 1.42)</td>
</tr>
</tbody>
</table>


**Notes:** *Oral type 2 diabetes drugs only, †Summary inclusion and exclusion criteria only, a: N with ACR at baseline and by 52w, b: Defined as ACR 30 μg/mg or below [or 30mg/g], c: Not defined, d: ACR greater than or equal to 30mg/g, e: elevated ACR included ‘micro’ albuminuria (30-300mg/g) and ‘macro’ albuminuria (≥300mg/g)
Table 2. Summary of study characteristics: Observational Studies.

| Author (Year) | Number | Data source (Country) | Yrs of study | Drug comparison | Age (yrs) | Kidney related exclusions | Measures at baseline | Primary outcomes of study | Follow-up (yrs) | Kidney outcomes recorded HR (95% CI)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hung et al. (2012)</td>
<td>93577</td>
<td>Veterans Administration (US)</td>
<td>2001–2008</td>
<td>Incident MTF, SU or RSG, excluding combination users</td>
<td>Median (IQR) MTF: 60 (55, 69) SU: 62 (56, 72) RSG: 64 (57, 72)</td>
<td>eGFR &lt;60</td>
<td>Microalbuminuria*: MTF: 3, SU: 3, RSG: 4 [only available for 15,065 people] Median eGFR (IQR) MTF: 81 (72, 93), SU: 80 (70, 93), RSG: 79 (69, 91)</td>
<td>eGFR event or ESRD Referent MTF: SU: 1.20, (1.13, 1.28), RSG: 0.92, (0.71, 1.18)</td>
<td>eGFR, ESRD or mortality Referent MTF: SU 1.20, (1.13, 1.28), RSG: 0.92, (0.69, 1.12)</td>
<td></td>
</tr>
<tr>
<td>Currie et al. (2013)</td>
<td>84,622</td>
<td>CPRD GOLD datalink (UK)</td>
<td>2000–2010</td>
<td>MTF, SU, MTF+SU</td>
<td>Mean (median) 61.9 (12.8)</td>
<td>None stated</td>
<td>Creatinine &gt;130 μmol/L: 4.5%</td>
<td>Mean (SD): 2.3 (SD 3.0)</td>
<td>Renal failure (Read codes) Mean: 2.8</td>
<td></td>
</tr>
<tr>
<td>Hung et al. (2013)</td>
<td>13238</td>
<td>Veterans Administration (US)</td>
<td>1999–2008</td>
<td>MTF, SU, MTF+SU</td>
<td>Median (IQR) MTF: 59 (54, 67) SU: 60 (54, 71) MTF+SU: 58 (53, 65)</td>
<td>Serum creatinine &gt;1.5 mg/dL or eGFR &lt; 60</td>
<td>eGFR Median (IQR) MTF: 81 (72, 93) SU: 80 (71, 93) MTF+SU: 82 (73, 97)</td>
<td>eGFR event or ESRD Referent: SU 2.63 (2.20, 3.15), MTF+SU: 1.39 (1.12, 1.72)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author (Year)</td>
<td>Number</td>
<td>Data source (Country)</td>
<td>Yrs of study</td>
<td>Drug comparison</td>
<td>Age (yrs)</td>
<td>Kidney related exclusions</td>
<td>Measures at baseline</td>
<td>Primary outcomes of study</td>
<td>Follow-up (yrs)</td>
<td>Kidney outcomes recorded HR (95% CI)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>-----------------------</td>
<td>--------------</td>
<td>-----------------</td>
<td>-----------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Masica et al. (2013)</td>
<td>798</td>
<td>Clinical data from primary care networks (US)</td>
<td>1998–2009</td>
<td>Exposure to drug (≥90d) MTF, SU, TZD, or combo</td>
<td>Mean (SD) MTF: 53.9 (11.9) SU: 53.7 (13.0) TZD: 53.9 (12.0)</td>
<td>Baseline proteinuria or MORD eGFR&lt;60</td>
<td>eGFR Mean (SD) Proteinuria analysis: MTF: 82.3 (20) SU: 79.5 (23) TZD: 75.6 (16) eGFR analysis: MTF: 86.8 (18) SU: 86.2 (21) TZD: 91.4 (34)</td>
<td>1 New proteinuria (24-hour albumin/ protein, spot protein, spot ACR, or dipstick) 2 New eGFR &lt;60</td>
<td>NR</td>
<td>8.0 % IPW group</td>
</tr>
<tr>
<td>Hippisley-Cox and Coupland (2016)</td>
<td>274,324</td>
<td>QResearch (UK)</td>
<td>2007–2015</td>
<td>DPP4i, TZD, MTF, SU, ‘other agents’</td>
<td>Mean (SD) TZD: 63 (12) DPP4i: 63 (12) MTF: 64 (13) SU: 66 (13) Other: 60 (12)</td>
<td>Kidney disease at baseline, and severe kidney disease</td>
<td>NR for kidney analysis: prior to kidney baseline exclusions: Creatinine μmol/L, mean (SD) TZD: 87 (34), DPP4i: 85 (33), MTF: 85 (30), SU: 92 (48)</td>
<td>% 1–3yrs since diagnosis: TZD: 28 DPP4i: 26 MTF: 25 SU: 24</td>
<td>NR</td>
<td>Incident severe kidney failure (Read codes for dialysis &amp; transplantation, or CKD stage 5 based on serum creatinine values)</td>
</tr>
<tr>
<td>Author (Year)</td>
<td>Number</td>
<td>Data source (Country)</td>
<td>Yrs of study</td>
<td>Drug comparison</td>
<td>Age (yrs)</td>
<td>Kidney related exclusions</td>
<td>Measures at baseline</td>
<td>Primary outcomes of study</td>
<td>Follow-up (yrs)</td>
<td>Kidney outcomes recorded HR (95% CI)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>-----------------------</td>
<td>--------------</td>
<td>----------------</td>
<td>----------</td>
<td>--------------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Kolaczynski et al. (2016)</td>
<td>5436 matched sample</td>
<td>IMS Lifelink (Germany)</td>
<td>2007–2013</td>
<td>SU, DPP4i</td>
<td>Mean (SD) SU: 63.7 (10.7) DPP4i: 64.6 (10.9)</td>
<td>History of nephropathy</td>
<td>Renal failure % (ICD-10 code) DPP4i: 13 SU: 11.1</td>
<td>Mean (SD) DPP4i: 3.1 (3.4) SU: 3.2 (3.4)</td>
<td>20</td>
<td>Incidence nephropathy (ICD-10 code) Mean (SD) DPP4i: 3.48 (3.75) SU: 2.49 (3.46)</td>
</tr>
<tr>
<td>Goldshtein et al. (2016)</td>
<td>564 matched sample</td>
<td>Maccabi Health Service diabetes registry (Israel)</td>
<td>2008–2014</td>
<td>MTF+SU, MTF+DPP4i</td>
<td>Mean (SD) SU: 58.5 (11) DPP4i: 59.1 (11.2)</td>
<td>Dialysis, eGFR &lt;45 or ACE/ARB in 90 day post index</td>
<td>ACR mg/g mean (SD) SU: 122.4 (194.5) DPP4i: 139.9 (261.9) eGFR mean (SD) SU: 84 (19.5), DPP4i: 82.4 (19.1)</td>
<td>Mean (SD) SU: 5 (3.5), DPP4i: 5.2 (3.5)</td>
<td>9</td>
<td>Improvements in urinary ACR (≥20% improvement in ACR and change in KDIGO category) Mean: 9 months, max 52 weeks</td>
</tr>
<tr>
<td>Carlson et al. (2016)</td>
<td>168,443 All Danish citizens</td>
<td></td>
<td>2000–2012</td>
<td>MTF, SU</td>
<td>Mean (SD) MTF: 65.7 (9.4) SU: 69.2 (10.8)</td>
<td>ESPR or eGFR &lt;30 ml/min/1.73m²</td>
<td>eGFR Median (IQR) MTF: 74 (63–87) SU: 69 (57–82)</td>
<td>NR</td>
<td>1</td>
<td>Acute dialysis 1y following treatment initiation</td>
</tr>
</tbody>
</table>

Abbreviations: ACR: Albumin: Creatinine Ratio, eGFR: estimated glomerular filtration rate, ESRD: End Stage Renal Disease, ICD: International Classification of Diseases, MTF: metformin, SU: sulfonylurea, TZD: Thiazolidinedione, DPP4i: Dipeptidyl peptidase-4 inhibitor, RSG: Rosiglitazone, STG: Sitagliptin, EXE: Exenatide, IPW: Inverse Probability Weight, FU: Follow-up, SD: Standard deviation, ARF: Acute Renal Failure, CKD: Chronic Kidney Disease, IQR: Inter Quartile Range, p-yr: person-years, NR: Not reported, DB: Database, KDIGO: Kidney Disease: Improving Global Outcomes Notes: a: MACE: Major adverse cardiac event: non-fatal MI, non-fatal stroke, or cardiovascular death, b: microalbuminuria if ACR was >30 mg/g, c: Hazard Ratio (HR), Mantel Haenszel (MH) or Odds Ratio (OR), eGFR units: ml/min/1.73m²
### Table 3. Results summary.

<table>
<thead>
<tr>
<th>Comparison</th>
<th>RCTs</th>
<th>Observational</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Results</td>
</tr>
<tr>
<td><strong>ACR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTF vs ACA</td>
<td>1</td>
<td>Favours ACA</td>
</tr>
<tr>
<td>MTF vs SU</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs TZD</td>
<td>2</td>
<td>Both favour TZD</td>
</tr>
<tr>
<td>SU vs SGLT</td>
<td>1</td>
<td>Favours SGLT</td>
</tr>
<tr>
<td>SU vs TZD</td>
<td>2</td>
<td>Both no difference</td>
</tr>
<tr>
<td><strong>Dual therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTF+SU vs MTF+DPP4i</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF+TZD vs MTF+SU</td>
<td>1</td>
<td>Favours MTF+TZD</td>
</tr>
<tr>
<td>SU+TZD vs SU+MTF</td>
<td>1</td>
<td>Favours SU+TZD</td>
</tr>
<tr>
<td><strong>eGFR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTF vs ACA</td>
<td>1</td>
<td>No difference</td>
</tr>
<tr>
<td>MTF vs SU</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs TZD</td>
<td>1</td>
<td>Favours TZD</td>
</tr>
<tr>
<td>SU vs SGLT</td>
<td>1</td>
<td>Favours SGLT</td>
</tr>
<tr>
<td>SU vs TZD</td>
<td>1</td>
<td>Favours TZD</td>
</tr>
<tr>
<td><strong>KIDNEY OUTCOMES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTF vs DPP4i</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs SU</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs TZD</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SU vs DPP4i</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Mono vs. dual therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTF vs MTF+DPP4i</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs MTF+SU</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs MTF+TZD</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs SU+DPP4i</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>MTF vs SU+TZD</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SU vs MTF+SU</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>


Most common drug for initiating treatment, and the addition of other drugs to metformin is likely to be associated with progression or poor control of type 2 DM, comparing metformin to drug prescribed at the first stage of intensification is problematic, particularly for renal outcomes. Those people receiving treatment intensification will tend to be sicker, and distinguishing between the effects of treatment and the effects of the underlying disease may not always be possible.
Conclusion

Key findings

Overall, we have found a lack of consistent evidence of long-term differences in kidney outcomes between T2DM drugs. In comparisons of treatments for type 2 DM, for thiazolidinediones vs metformin, there is some evidence of reduced proteinuria - of four comparisons with ACR as an outcome (in combination or monotherapy), three favoured TZD and one showed no difference. Most evidence from observational research also suggested that metformin is associated with better kidney outcomes than sulfonylureas.

Despite frequent use of combination therapies for the treatment of diabetes, we found few studies that compared commonly used dual therapies that investigated renal outcomes.

Previous work

The finding that thiazolidinediones may reduce proteinuria compared with metformin is aligned with observations of other authors and supported by animal studies. Though previous evidence is limited, other work suggests that TZDs could exert renoprotective effects via a number of pathways, including reducing blood pressure. TZDs may also act directly in the kidneys via proliferator-activated receptor gamma (PPARγ), found in the kidney (and in other tissues). However, changes in estimated GFR may reflect changes in fluid status rather than true changes in renal function, which was not measured directly in any study.

Strengths

To our knowledge, this is the first systematic review of the comparative research literature that investigated the effects of type 2 diabetes drug regimens on renal function. We have conducted an extensive and detailed search, with broad definitions of renal function.

Limitations

We have focused on renal outcomes only but recognize this is just one of many safety and effectiveness factors to be considered when deciding treatment options. Despite the importance of careful monitoring and maintenance of kidney function for people with diabetes, we identified just 15 long-term studies reporting renal outcomes. Renal complications of type 2 diabetes take many years to develop after the onset of diabetes and studies may not be adequately powered or have sufficient length of follow-up to detect differences. Therefore, many studies have used the surrogate marker of changes in proteinuria as a marker of clinical renal outcomes. Further, initial changes in kidney function may be misleading. One included study indicates benefits of canagliflozin over glinipiride for kidney function decline at 104 weeks: however these benefits were not apparent until 52 weeks. This and the EMPA-REG study have indicated initial acute falls in eGFR with better outcomes compared to placebo only observed over the longer term so this would not be apparent in short-term studies.

Our review included both randomised and non-interventional studies. Whilst the unique inferential advantages of randomization are clear, our review highlights a large overall difference in population size depending on study type: randomised trials generally included hundreds of patients, whilst non-interventional studies often had tens of thousands of participants. Rarer outcomes such as ESRD are therefore more likely to be detected in non-interventional settings. This highlights their important role, but the evidence generated from them needs to be evaluated cautiously due to the potential for bias and confounding.

The available evidence does not reflect drugs currently prescribed in routine care. In our review, 69% (22/32) of the comparisons, contrasted different monotherapies, with just three comparisons between dual therapy combinations. In clinical practice, metformin is the most common first-line therapy, and GPs now rarely prescribe thiazolidinediones (EU marketing authorization for Rosiglitazone was suspended in 2010, following concern regarding increased heart failure risk). In the UK, NICE guidance recommends the addition of sulfonylureas, Dipeptidyl peptidase-4 inhibitors (DPP4is) Sodium-glucose Cotransporter 2 Inhibitors (SGLT2is), or TZDs to metformin, yet, just one study compared these combinations (MTF+SU vs MTF+DPP4i). Recent studies that have shown potentially exciting improvements in renal outcomes for patients treated with SGLT2is were conducted against placebo and so were not eligible for this study.

We found that definitions of kidney outcomes were not consistent across studies. Definitions of renal decline in the observational studies relied upon either codes for kidney disease (e.g. diabetic nephropathy, acute renal failure), surrogate markers (e.g. eGFR or proteinuria) or a combination of codes and tests, summarised in Supplementary Table 4. For the albuminuria data, which has a skewed distribution, most studies used logarithmic transformation to approximate normal, yet not all studies applied this method. Such differences between outcomes will limit future opportunities for pooling effect estimates in meta-analyses. Different approaches to study design may also limit the validity of findings. We found two observational studies that made the same comparisons yet found different effects. Both examined renal failure, using UK primary care data, (QResearch and Clinical Practice Research Datalink). They found comparable effect sizes when comparing the use of sulfonylurea monotherapy to metformin monotherapy, for renal failure (2.63, 95% CI: 2.25, 3.06 and 2.63, 95% CI: 2.19, 3.15). However, when comparing sulfonylurea plus metformin dual therapy to metformin monotherapy, estimates of the risk of kidney failure were in opposite directions (0.76, 95% CI: 0.62, 0.92 and 1.39, 95% CI: 1.12, 1.72). Difficulties in adjusting for levels of diabetic control or change in renal function that led to these treatment choices (confounding by indication), may explain these conflicting results.

In the randomised controlled studies, we found that eligibility criteria were strict. Many studies excluded people most at risk of kidney outcomes e.g. those with reduced kidney function or cardiovascular disease. These restrictions limit the generalisability of study findings to routine clinical settings where
people presenting with diabetes have complex comorbidities. Further, as most individuals with type 2 diabetes will receive treatment for other comorbid conditions, prescribers need to know how diabetic therapies interact with concomitant drugs, yet this is not addressed by the studies identified in this review.

Clinical relevance
In clinical practice, kidney function is one of many considerations for treatment choice in type 2 DM. Some of the differences we found for albuminuria and eGFR between people taking different oral therapies for type 2 diabetes were statistically significant, but the clinical importance of these findings may be limited. Some surrogate outcomes such as a doubling of creatinine or 30% decline in eGFR are closely associated with risk of future ESRD, while ACR is not. Outcomes that are clinically relevant need to be assessed in future studies. Ideally, these should include hard outcomes such as hospital admission with acute kidney injury or the development of ESRD. Therefore, large, well-designed studies with long follow up, including individuals that represent the typical type 2 diabetes population, will be required. However, the incidence of kidney outcomes is likely to be low in most randomised trials and therefore high-quality observational studies will also be needed.

Our review highlights a lack of rigorous studies comparing the effects of oral type 2 diabetes drugs on kidney outcomes, in particular, for the newer drug intensification options where prescribing is rapidly increasing.

Data availability
All data underlying the results are available as part of the article and supplementary material no additional source data are required.

Competing interests
SW is funded by a GSK PhD scholarship. HS is an employee of and holds shares in GSK. LAT reports no competing interests. IJD is funded by, holds stock in and has consulted for GSK. LS is funded by a fellowship from the Wellcome Trust and consults for GSK and AstraZeneca, has received grants from the European Union and is a Trustee of the British Heart Foundation.

Grant information
This work was supported by the Wellcome Trust through a Wellcome Trust intermediate clinical fellowship to LAT [101143] and a Wellcome Trust Senior Research Fellowship in Clinical Science to LS [098504].

This review was also supported by GlaxoSmithKline (GSK), through a PhD scholarship for SW. HS-F is a full-time employee of GSK. MI is supported by the Honjo International Scholarship Foundation. IJD is paid by an unrestricted grant from GSK.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary material
Supplementary File 1 – Completed PRISMA checklist
Click here to access the data.

Supplementary File 2 – File contain the following supplementary tables.
Click here to access the data.

Supplementary Table 1: First Ovid Medline search
Supplementary Table 2: First search Web of science
Supplementary Table 3: Report of further comparisons from Hippisley-Cox and Coupland (2016) paper
Supplementary Table 4: Detailed definitions of composite renal outcomes for observational studies
Supplementary Table 5: GRACE 2014 items for observational studies
Supplementary Table 6: Cochrane items for quality of RCT studies

References
Page 14 of 16

Wellcome Open Research 2018, 3:74 Last updated: 25 JUN 2018


Open Peer Review

Current Referee Status: ✓

Version 1

Referee Report 25 June 2018

doi:10.21956/wellcomeopenres.15962.r33343

William G. Herrington 1,2
1 Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Oxford, UK
2 Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK

I like the approach to article screening by random checking rather than duplicating reviewer work in its entirety. This could be risk-based in future reviews.

My only comments relate to the discussion:

1. The authors state “most evidence from observational research also suggested that metformin is associated with better kidney outcomes than sulphonylureas”. Indirect comparison could be a good sanity check that this is as expected. For example, do the placebo-controlled trials show that metformin has beneficial effects on kidney outcomes and do placebo-controlled trials of sulphonylureas predict they may differ?

2. The penultimate paragraph concludes that: “….high-quality observational studies are needed” to address the effect of different antidiabetes drugs on ESRD or hospitalization with acute kidney injury. As the authors acknowledge, such studies require careful adjustment for confounders. The particular challenges this poses in populations with type 2 diabetes could be more clearly highlighted in the discussion. First, co-morbidity and co-medication are common, which increases the number of covariates required for reliable findings to emerge. Secondly, complete and precise measurement of all relevant confounders are difficult to ensure. For example, HbA1c, BP and RAS-inhibition use throughout the observation period (and arguably in the period which precedes it) would all be important to consider adjusting for, but measurement error is common for these parameters and defining and using covariates can be problematic (e.g. differences in RAS-inhibition formulations, doses and adherence).

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Partly

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

**Competing Interests:** I have received funding from the MRC-UK, Kidney Research UK, the BHF and Boehringer Ingelheim

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.